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Background: The aim of the present study was to measure the serum level of dickkopf-1(DKK-1) in patients with
non-small cell lung cancer (NSCLC), and to determine the prognostic potential of serum DKK-1 in NSCLC.
Material and methods: The present study included a total of 150 patients with NSCLC and 150 healthy controls.
Serum level of DKK-1 was measured by enzyme-linked immunosorbent assay (ELISA). Numerical variables were
recorded as means ± standard deviation (SD) and analyzed by independent t-tests. Categorical variables were
presented as rates and analyzed by using the chi-square test or Fisher’s exact test. The overall survival was analyzed
by log-rank test, and survival curves were plotted according to Kaplan–Meier.
Results: We found that serum DKK-1 level was significantly higher in patients with NSCLC than healthy controls.
Mean serum DKK-1 level was 31.42 ± 6.32 ng/ml in the NSCLC group and 14.12 ± 3.29 ng/ml in the healthy control
group (p <0.01). Serum DKK-1 level expression level was significantly positively correlated with TNM stage
(p = 0.009), lymph node involvement(p = 0.001), and distant metastases(p < 0.001).
In the multivariate Cox proportional hazards analysis, high DKK-1 expression was independently associated with
poor survival (P < 0.001; HR = 3.98; 95% CI =2.19-4.83).
Conclusions: In conclusion, our results showed that DKK-1 was overexpressed in NSCLC, and DKK-1 in serum was a
good predictor of poor prognosis in patients with NSCLC. More researches are needed in the future to clarify the
detailed mechanism of DKK-1 in the carcinogenesis and metastasis of NSCLC.
Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1471414150119415.
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Lung cancer is one of the leading causes of all cancer re-
lated deaths worldwide, with a 5-year survival as low as
13% [1]. Non small cell lung cancer (NSCLC) represents
approximately 85% of lung cancer cases and comprises
several histological phenotypes, the most common being
adenocarcinoma, squamous-cell carcinoma and large-
cell carcinoma. When dealing with NSCLC, we still face
a lot of clinical problems. Most patients have locally ad-
vanced or metastatic disease at the time of diagnosis,
and only a third of NSCLC cases are considered technic-
ally and oncologically treatable with a radical surgical* Correspondence: dr_zhangxiaohui@126.com; dr_liuyinghui@126.com
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unless otherwise stated.intervention [2]. The overall prognosis of NSCLC is poor,
because it exhibits high resistance to anticancer therapy
[1]. A promising breakthrough to improve the outcome
for NSCLC patients is the introduction of validated bio-
markers into clinical management. These may be crucial
not only for early diagnosis but also to assist treatment
choice for the most optimal therapeutic interventions.
Previous studies have shown that the Wnt signaling
pathway regulated proliferation, fate specification, po-
larity and migration of cells [3,4]. The Dickkopf (DKK)
family of proteins are known as antagonists for the Wnt-β-
catenin signalling pathway, which includes DKK-1, DKK-2,
DKK-3 and DKK-4 [5]. DKK-1 encodes a secreted Wnt an-
tagonist that binds to LRP5/6 and so induces its endocyto-
sis, leading to the inhibition of the canonical pathway [6].
DKK-1 itself is a target of the beta- catenin/TCF signalingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sion of DKK-1 was down-regulated significantly in human
colon cancer, gastric cancer and melanoma [7-9]. How-
ever, paradoxically, DKK-1 has been found to be overex-
pressed in hepatoblastomas, hepatocellular carcinomas,
and Wilms’ tumors [10,11], suggesting that the function of
DKK-1 may be different in different cancers. Previous
studies have investigated the expression and functions of
several proteins in lung cancer [12-16]. However, the ex-
pression level of DKK-1 in primary lung cancer and its re-
lationship with clinicopathological factors has not been
examined, therefore, and the biological roles of DKK-1 in
lung cancer cells are still unclear.
In the present study, we measured the serum levels of
DKK-1 in patients with NSCLC and healthy controls. We
sought to determine the prognostic potential of DKK-1 in
NSCLC.Table 1 Clinical features of patients with non–small cell
lung cancer and controls
Variables Patients (N = 150) Controls (n = 150) P value
Age
Mean (SD), yr 64.2 ± 15.1 62.1 ± 14.3
< 50 yr 15 18
50-70 yr 85 83
> 70 yr 50 49 >0.05
Sex
Male 81 77
Female 69 73 >0.05
N: number; SD: Standard Deviation.Materials and methods
Patient, healthy controls, and serum samples
The selection criteria for patients with NSCLC were as fol-
lows: (1) pathologically confirmed patients with NSCLC
(the diagnoses in all patients were confirmed each time by
microscopic examination of the material obtained during
bronchoscopy, biopsy, and/or surgery); (2) the patients
had no history of other cancers. A total of 150 patients
with NSCLC in Yantai Yuhuangding Hospital between
June 2006 and July 2012 were enrolled in the present
study. All subjects underwent clinical examination; plain
chest radiograph; CT scan of the chest, upper abdomen,
and brain; fiberoptic bronchoscopy; and bone scan. Blood
samples were collected from the patients at the time of
diagnosis, before any kind of treatment (surgery, radiation,
or chemotherapy). The demographic and pathological
data, including age, gender, and the tumor stage were
obtained by a review of the patients’ medical records
(the data was used with the consent of the patients as
well as the approval of the Ethics Committee of Yantai
Yuhuangding Hospital). Tumor stage was determined
according to the 2009 TNM staging classification sys-
tem. Fasting blood was taken for all participants and
serum was collected and stored at −80°C.
Enzyme-linked immunosorbent assay
Serum DKK-1 levels were measured by enzyme-linked
immunosorbent assay (ELISA) with immunoassay kit
(Miltenyi, Germany) according to the manufacturer’s di-
rections. The optical density (OD) at 450 nm was deter-
mined. The standard curves were established with
OD450 as Y axle and the concentration of standard sub-
stance as X axle. The level of protein was obtained
through standard curve. Results were reported as con-
centration of DKK-1 ng/ml in samples.Statistical analysis
Statistical analyses were performed using SPSS 13.0 soft-
ware (Chicago, Ill., U SA) and GraphPad Prism 5 (Graph-
Pad Software Inc., CA, USA). Numerical variables were
recorded as means ± SD and analyzed by independent t-
tests. Categorical variables were presented as rates and ana-
lyzed by using the chi-square test or Fisher’s exact test. The
overall survival was analyzed by log-rank test, and survival
curves were plotted according to Kaplan–Meier. Univariate
Cox regression was performed on each clinical covariate to
examine its influence on patient survival. Final multivariate
models were based on step-wise addition. P-values <0.05
was considered as statistically significant.Results
Clinical features of patients with NSCLC and healthy
controls
150 patients with recently diagnosed NSCLC were en-
rolled in the present study, and 150 healthy persons were
used as a control group. Among the 150 patients with
NSCLC, 65 patients were treated with surgery. Mean age
was 64.2 ± 15.1 yr in the NSCLC group and 62.1 ± 14.3 yr
in the control group (P>0.05). There were 81 males and
69 females in the NSCLC group, and 77 males and 73 fe-
males in the control group (P>0.05). The clinical features
of 150 patients with NSCLC and 150 controls was sum-
marized in Table 1.The serum level of DKK-1 in patients with NSCLC
and controls
Serum DKK-1 level was found to be significantly higher in
patients with NSCLC than controls. Mean serum DKK-1
level was 31.42 ± 6.32 ng/ml in the NSCLC group and
14.12 ± 3.29 ng/ml in the control group (p <0.01) (Figure 1).
The 95th percentile of DKK-1 values of the control group
was 22.1 ng/ml, which was used as the cutoff value.
Figure 1 Serum DKK-1 levels in patients with NSCLC and
controls. Mean serum DKK-1 level was 31.42 ± 6.32 ng/ml in the
NSCLC group and 14.12 ± 3.29 ng/ml in the control group (p <0.01).
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characteristics and survival analyses
As shown in Table 2, serum DKK-1 level expression
levels were significantly positively correlated with TNM
stage (p = 0.009), lymph node involvement (p = 0.001),Table 2 Relation of serum DKK-1 to clinicopathological
characteristics of 150 patients with non–small cell
lung cancer
Group N (%) DKK-1,ng/ml (mean[SD]) P value
Gender
Male 81(54%) 32.1(6.1)
Female 69(46%) 30.2(5.9) 0.91
Age
< 50 yr 15(10%) 29.9(3.6)
50-70 yr 85(57%) 32.3(6.1)









IV 58(39%) 49.1(6.7) 0.009
Lymph node
No 103(69%) 24.3(6.6)
Yes 47(31%) 57.9(3.9) 0.001
Distant metastases
No 135(90%) 23.2(9.3)
Yes 15(10%) 68.1(7.9) <0.001
N: number; SD: Standard Deviation.and distant metastases (p < 0.001). However, no signifi-
cant correlation was observed between serum DKK-1
level and other clinicopathologic parameters, including
age (P = 0.77), gender(P = 0.91), and smoking history
(P = 0.81). We then detected whether the serum expres-
sion level of DKK-1 would be of any prognostic rele-
vance in NSCLC. For this purpose, we performed
survival analysis. As shown in Figure 2A, among all of
the 150 patients with NSCLC, the patients with higher
levels of serum DKK-1 had significantly poorer survival
than those with lower expression levels of DKK-1, with
a 5-year overall survival of 11.27% and 50.42%, respect-
ively (P = 0.0027). Among the 65 patients treated with
surgery, the patients with higher levels of serum DKK-1
had significantly poorer survival than those with lower
expression levels of DKK-1, with a 5-year overall sur-
vival of 27.69% and 66.69%, respectively (P = 0.0033,
shown in Figure 2B).
A Cox proportional hazards analysis was used to further
evaluate the potential of serum DKK-1 expression level as
a prognostic biomarker. Univariate survival analysesFigure 2 Kaplan –Meier curves for patients with NSCLC. (A).
Kaplan–Meier survival curve in relation to serum DKK-1 level in 150
patients with NSCLC. (B). Kaplan–Meier survival curve in relation to
serum DKK-1 level in 65 patients treated with surgery.
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lymph node involvement, and distant metastases were as-
sociated with prognosis, while gender, age, and smoking
status were not associated with prognosis. In the multi-
variate Cox proportional hazards analysis, which included
gender, age, smoking status, serum DKK-1 expression level,
TNM stage, lymph node involvement, and distant metasta-
ses, high DKK-1 expression was independently associated
with poor survival (P < 0.001; HR = 3.98; 95% CI =2.19-
4.83, shown in Table 3).
Discussion
As we know, the Wnt pathway plays an important role in
development and in regulating adult stem cell systems, and
aberrant activation of the Wnt signaling pathway is a major
trait of many human cancers, including colorectal cancer,
melanoma, NSCLC, leukemia, and bladder cancer [17]. A
variety of cellular processes are mediated by Wnt signaling,
including proliferation, differentiation, survival, apoptosis,
and cell motility [18]. Wnts include negative and positive
regulators, which act either intracellularly to modulate
components of the signal transduction machinery or extra-
cellularly to modulate ligand receptor interactions. Extracel-
lular Wnt antagonists are composed of 5 families: the
secreted frizzled-related protein, Wnt inhibitory factor 1,
Xenopus Cerberus, Wise, and the DKK family [19].
The DKK family encodes secreted proteins, consisting
of DKK-1, DKK-2, DKK-3, DKK-4, and a unique DKK-3-
related gene, called Soggy. DKK-1, DKK-2, DKK-3, and
DKK-4 contain two discrete cysteine-rich domains, in
which the positions of 10 cysteine residues are supremely
conserved among family members. DKK-1 binds to low-
density lipoprotein receptor related protein-5/6 and blocks
interaction with Wnt-1, resulting in β-catenin degradation
and effects on proliferation [20,21]. Another study showed
that DKK-1 functioned not only as an antagonist of the
Wnt/β-catenin pathway but also as an agent that could
upregulate other Wnt signaling pathways if the requisite
Wnt/receptor combinations were available [22]. DKK-1
also can suppress cell growth and induces apoptotic cell
death by activating the c-Jun N-terminal kinase pathwayTable 3 Multivariate analyses for prognostic factors in
patients with NSCLC
Variables HR 95% CI P value
Age 1.31 0.79-1.46 0.81
Sex 0.91 0.88-1.36 0.79
Smoking history 1.98 0.97-2.13 0.06
TNM stage 2.39 2.13-3.89 0.001
Lymph node involvement 2.13 1.99-4.12 0.002
Distant metastases 5.97 3.12-9.33 <0.001
DKK-1 in serum 3.98 2.19-4.83 <0.001
CI, confidence interval; HR, hazard ratio.[23]. Previous studies have shown that the expression of
DKK-1 was down-regulated significantly in human colon
cancer, gastric cancer and melanoma, suggesting that
DKK-1 may act as a tumor suppressor in these cancers
and its role as an antagonist of Wnt signaling is lost in
these cancers. However, paradoxically, DKK-1 has been
found to be over expressed in hepatoblastoma and hepato-
cellular carcinoma, suggesting that DKK-1 may be feed-
back regulated by activated Wnt signaling pathway. It also
means that the function of DKK-1 may differ depending
on the cancer type.
Since DKK-1 is a secreted protein, serum level of DKK-1
and its prognostic potential have been investigated in sev-
eral cancers. For example, Yang H et al. found that the
mean serum level of DKK-1 in patients with early hepato-
cellular carcinoma was significantly higher than that in pa-
tients with cirrhosis, noncirrhotic chronic hepatitis B,
benign liver tumors and healthy individuals (p < 0.001).
The patients with a high serum DKK-1 level had a poorer
overall survival (p = 0.028) and relapse-free survival (p =
0.045) than those with a low expression level [24]. Re-
cently, Jiang T et al. found that the levels of serum DKK-1
were significantly increased in patients with cervical can-
cer compared with healthy women and patients with cer-
vical intraepithelial neoplasia (p < 0.001). Further more,
the expression level of DKK-1 in serum was correlated
with lymphatic metastasis and tumor diameter in cervical
cancer and associated with the prognosis of patients with
cervical cancer [25].
In the present study, we investigated whether DKK-1
was secreted into the serum of patients with NSCLC. Our
results showed that the levels of serum DKK-1 were sig-
nificantly increased in patients with NSCLC compared
with healthy controls. Further more, we found that serum
DKK-1 level expression levels were significantly positively
correlated with TNM stage, lymph node involvement, and
distant metastases, suggesting that DKK-1 might be in-
volved in the carcinogenesis and metastasis of NSCLC.
More importantly, we proved that patients with a high ex-
pression of DKK-1 tended to have shorter survival than
patients with lower levels, indicating that high DKK-1 level
was a marker of poor prognosis for patients with NSCLC.
However, in the present study, we have not investigated
the detailed mechanism of DKK-1 in the carcinogenesis
and metastasis of NSCLC.
In conclusion, our results showed that DKK-1 was over-
expressed in NSCLC, and DKK-1 in serum was a good
predictor of poor prognosis in patients with NSCLC. More
researches are needed in the future to clarify the detailed
mechanism of DKK-1 in the carcinogenesis and metastasis
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